FDA Clearance: MagVenture TMS Therapy Indication Expanded for Adolescents (Ages 15–21)

MagVenture has received FDA clearance to expand its TMS Therapy system as an adjunct treatment for Major Depressive Disorder (MDD) in adolescent patients aged 15 to 21 who have not responded to prior medications.